Godavari Biorefineries Reports Strong Q3 FY26 Performance with 14% EBITDA Growth
Godavari Biorefineries Limited reported strong Q3 FY26 results with EBITDA growing 13.80% to INR45.10 crores and profit before tax surging 152.20% to INR21.40 crores. The bio-based chemicals segment showed significant margin improvement to 7.70%, while the consumer brand Jivana crossed INR100 crores revenue milestone. The company secured a US patent for anti-cancer molecule and established Sathgen Therapeutics LLC subsidiary for IP commercialization.
*this image is generated using AI for illustrative purposes only.
Godavari Biorefineries Limited delivered strong financial performance in Q3 FY26, demonstrating significant improvement in profitability and operational efficiency. The company's strategic focus on high-margin specialty chemicals and disciplined cost management translated into robust earnings growth during the quarter.
Financial Performance Highlights
The company reported impressive financial metrics for Q3 FY26, with total income reaching INR461.90 crores, representing a 2.50% year-on-year growth. Despite modest revenue growth, the quality of earnings improved substantially across key parameters.
| Metric | Q3 FY26 | Q3 FY25 | Growth (%) |
|---|---|---|---|
| Total Income | INR461.90 crores | INR450.80 crores | +2.50% |
| EBITDA | INR45.10 crores | INR39.70 crores | +13.80% |
| EBITDA Margin | 9.80% | 8.83% | +97 bps |
| PBT (before exceptional) | INR21.40 crores | INR8.40 crores | +152.20% |
For the nine-month period, total income stood at INR1430.20 crores compared to INR1298.20 crores in the previous year. EBITDA improved dramatically to INR47.20 crores from a marginal loss of INR1.40 crores, with margins strengthening to 3.30% from negative levels.
Segment-wise Performance
The bio-based chemicals business emerged as a key profitability driver, supported by an increased share of specialty and value-added products. The segment's EBITDA margin improved significantly to 7.70% in Q3 FY26 compared to 4.50% in the corresponding quarter last year.
Specialty chemicals contributed 62% of the chemical basket during the nine-month period, reflecting the company's successful strategy of transitioning toward higher-margin products. The ethanol segment experienced some softness during the quarter, while the sugar and cogeneration segment operated in line with the seasonal crushing cycle.
Strategic Initiatives and Innovation
The company advanced several strategic initiatives during the quarter, with notable progress in research and development. A significant milestone was the grant of a US patent for a novel anti-cancer molecule targeting Triple Negative Breast Cancer, highlighting the strength of the company's research capabilities.
| Development | Details |
|---|---|
| US Patent | Anti-cancer molecule for Triple Negative Breast Cancer |
| New Subsidiary | Sathgen Therapeutics LLC incorporated in the US |
| Technology Initiative | DME to CO2 pilot plant activities underway |
| Partnership | Collaboration with Synthomer for bio-based monomers |
The company incorporated Sathgen Therapeutics LLC in the US as a wholly-owned step-down subsidiary to market its intellectual property and pursue out-licensing partnerships. Additionally, the DME to CO2 technology initiative is progressing well with pilot plant activities currently underway.
Consumer Business Growth
The consumer business segment gained significant momentum during the period. The company's brand portfolio Jivana crossed the INR100 crores revenue milestone during the nine months of FY26, validating the strategy of building a balanced business model that combines industrial strength with consumer-facing growth.
The brand now operates across approximately 7,500 plus outlets, representing expansion from 7,000 plus outlets in the previous quarter. While this segment remains in a scaling phase, management sees long-term potential as the company expands distribution, strengthens brand presence, and deepens product offerings.
Operational Developments
The company is implementing capacity expansion initiatives, including the commissioning of a grain-based distillery facility. Originally expected in Q3 FY26, the facility is now anticipated to be commissioned by the next quarter due to equipment delivery delays from vendors.
Finance costs declined by 48% year-on-year, reflecting sustained efforts to strengthen cash flows and improve the balance sheet. The company's capital allocation strategy includes an estimated capex of INR325 crores to achieve 3x EBITDA by FY29, with 75% allocated to bio-based chemicals and 25% to ethanol capacity expansion.
